Jack Scheuer, MD
Internal Medicine · Camden, SCNPI 1871544403
Payments from drug & device makers
Across 233 payments — averaging $45.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$7K
- AbbVie$631
- AstraZeneca$423
- Pfizer$356
- GSK$304
- Johnson & Johnson$283
- plus $2K from 23 others
What the payments were for
- Food & beverage$3,740100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 7 | $6,872 |
| AbbVie(2 entities) | 26 | $631 |
| AstraZeneca | 28 | $423 |
| Pfizer | 26 | $356 |
| GSK | 26 | $304 |
| Johnson & Johnson | 15 | $283 |
| Novo Nordisk | 11 | $233 |
| Amgen | 15 | $232 |
| Teva Pharmaceuticals USA, Inc. | 11 | $181 |
| Amarin Pharma, Inc. | 14 | $171 |
| Davol Inc. | 1 | $118 |
| Merck | 9 | $116 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $102 |
| Boehringer Ingelheim | 6 | $90 |
| Kowa Pharmaceuticals America, Inc. | 7 | $85 |
| Sanofi-aventis U.S. LLC | 5 | $71 |
| Astellas Pharma US Inc | 4 | $55 |
| Grifols USA, LLC | 2 | $46 |
| Medtronic | 1 | $25 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 3 | $19 |
| Nestle Healthcare Nutrition Inc. | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Boston Scientific | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Eisai Inc. | 1 | $12 |
| Mylan Specialty L.p. | 1 | $12 |
| Seqirus USA Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX COSMETIC$126
- Phasix Mesh$118
- COLOGUARD$105
- Ozempic$102
How this compares
$10,549 in reported general payments places this provider in the 95th percentile of 1,498 internal medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 255 | $214,225 |
| EliquisApixaban | 281 | $156,522 |
| OzempicSemaglutide | 70 | $100,211 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 61 | $81,824 |
| TrulicityDulaglutide | 29 | $42,979 |
| EntrestoSacubitril/Valsartan | 46 | $42,175 |
| JanuviaSitagliptin Phosphate | 27 | $30,310 |
| TivicayDolutegravir Sodium | 12 | $28,333 |
| JanumetSitagliptin Phos/Metformin Hcl | 27 | $28,153 |
| XifaxanRifaximin | 12 | $26,973 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $26,400 |
| DescovyEmtricitabine/Tenofov Alafenam | 11 | $25,873 |
| MyrbetriqMirabegron | 24 | $22,294 |
| FarxigaDapagliflozin Propanediol | 18 | $18,396 |
| NuedextaDextromethorphan Hbr/Quinidine | 22 | $15,593 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $90 | $221,578274 claims |
| PfizerEliquis | $356 | $156,522281 claims |
| Novo NordiskOzempic, Rybelsus | $233 | $114,49682 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $71 | $81,82461 claims |
| MerckJanuvia, Janumet | $116 | $58,46354 claims |
| NovartisEntresto | $6,872 | $42,17546 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $304 | $40,58251 claims |
| AstraZenecaFarxiga, Symbicort | $423 | $29,16052 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $102 | $26,97312 claims |
| Astellas Pharma US IncMyrbetriq | $55 | $22,29424 claims |
| Johnson & JohnsonXarelto | $283 | $15,02328 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $19 | $5,15219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Camden
- Rica SantiagoMt Pleasant$10.7M
- Richard MillsMt Pleasant$5.5M
- Yvonne DavisMount Pleasant$2.4M
- David BolsterSummerville$2.3M
- Colby GrossmanSummerville$1.4M
- Amit ShahIndian Land$1.4M
- Philip NicolMurrells Inlet$782K
- Carl SofleyAnderson$673K
- Carl MitchellColumbia$564K
- Jerry BackNorth Charleston$322K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.